Clinical trials
Relapsed or Refractory Large B-cell Lymphoma clinical trials
Below are recruiting relapsed or refractory large b-cell lymphoma clinical trials, each written for real people, not researchers. We’re tracking 1,747 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07185373RecruitingPhase 2/Phase 3
Newly diagnosed CNS lymphoma with orelabrutinib combination therapy
This trial tests a combination of targeted and chemotherapy drugs for people newly diagnosed with primary central nervous system lymphoma. It aims to see if the combination works better than standard treatment.
BeijingAges 18–75 - NCT07285239RecruitingPhase 3
Comparing two drug combinations for newly diagnosed multiple myeloma
This trial compares two different combinations of medications for people with newly diagnosed multiple myeloma who are not planning to have a stem cell transplant. It looks at whether adding a targeted antibody drug is as effective as the standard approach.
La Crosse, WisconsinAges 18–79 - NCT04728893RecruitingPhase 2
Nemtabrutinib for blood cancers after prior treatment
This Phase 2 trial tests nemtabrutinib (MK-1026), an oral medicine, in people with certain blood cancers that have come back or didn’t respond to earlier treatments. It aims to see how well the drug works and whether it is safe.
Springdale, ArkansasAges 18 years+ - NCT04515810Recruiting
Mobile app coaching for planning care after serious cancer
This study tests a mobile health app (PACT) to help people with advanced cancer talk and plan for future care. It may help you and a loved one stay engaged in advance care planning (planning what care you want and who should speak for you).
Manhasset, New YorkAges 18 years+ - NCT05958381Recruiting
Brain stimulation for memory problems in relapsing MS
This trial studies a noninvasive brain stimulation treatment to improve memory (specifically memory recall) in people with relapsing-remitting multiple sclerosis (RRMS). It may help if your memory testing shows a “retrieval” problem, and if you’re able to follow the study treatment and safety requirements.
Richardson, TexasAges 18–65 - NCT05748171RecruitingPhase 2
Testing inotuzumab for children with early ALL relapse
This Phase 2 study tests inotuzumab ozogamicin (InO), a cancer medicine, in children aged 1 to under 18 with a first relapse of ALL. It aims to find out how well and safely the medicine works when the leukemia comes back early.
ViennaAges 1–17 - NCT05444348Recruiting
Communication and care-planning support for blood cancer patients
This study tests an approach to help people with certain blood cancers and their main caregiver plan ahead and communicate more clearly about end-of-life care. It may help patients feel more supported and better prepared for difficult decisions.
AalborgAges 18 years+ - NCT04696029RecruitingPhase 2
DFMO to prevent return of high-risk or relapsed medulloblastoma
This Phase 2 study tests DFMO (a maintenance medicine) to help stop medulloblastoma from coming back or worsening after prior treatment. It focuses on children and young people with specific high-risk tumor types or tumors that have returned or not responded well to treatment.
Little Rock, ArkansasAges Up to 21 years - NCT07758270Recruiting
Brain scan study for multiple sclerosis treatment switch
This study looks at how a new pill for multiple sclerosis (MS) affects brain inflammation and immune cells. It may help people who are already taking an MS medication but want to switch to a different one.
St Louis, MissouriAges 40–70 - NCT05057702Recruiting
Personalized surgery-focused treatment plan for relapsed brain cancer
This study tests a personalized treatment plan for children and young adults whose medulloblastoma or ependymoma has come back. It aims to guide doctors using new tissue from surgery or biopsy after earlier treatments are fully finished.
Los Angeles, CaliforniaAges 1–39 - NCT05470491RecruitingPhase 1/Phase 2
Haploidentical bone marrow transplant with GVHD prevention drugs
This trial tests a reduced-intensity bone marrow transplant from a related donor (haploidentical), using medicines to help prevent a serious complication called GVHD. It is for people with certain blood cancers and aims to improve outcomes by balancing transplant benefit with lower treatment intensity.
Bethesda, MarylandAges 12–120 - NCT05285891RecruitingPhase 4
Stopping ocrelizumab in early relapsing multiple sclerosis
This study looks at whether people with early relapsing multiple sclerosis can safely stop ocrelizumab. Researchers will compare health and MRI findings over time to see if stopping helps or increases relapse risk.
New Haven, ConnecticutAges 18–55 - NCT05512364RecruitingPhase 3
Elacestrant for ER-positive, HER2-negative breast cancer with ctDNA relapse
This trial tests whether elacestrant can help stop or delay breast cancer coming back in people whose blood test shows “ctDNA relapse” after early breast cancer treatment. It’s meant for hormone receptor–positive, HER2-negative breast cancer patients who are already taking hormone (endocrine) therapy and have no visible spread on scans.
AnderlechtAges 18 years+ - NCT07704658RecruitingPhase 4
Pralsetinib drug interaction study for advanced solid tumors
This trial tests how pralsetinib interacts with other drugs in people with advanced solid tumors that have a specific RET gene change. It aims to find the right dose and safety profile.
Logroño, La RiojaAges 18 years+ - NCT06285825RecruitingPhase 2
Study of emapalumab for low blood counts after CAR T-cell therapy
This study tests a drug called emapalumab to help people whose blood counts stay low for weeks after CAR T-cell therapy for certain types of lymphoma. The goal is to see if the drug can help the body recover normal blood cell production.
Houston, TexasAges 18 years+ - NCT06232213Recruiting
Personalized treatment for relapsed or drug-resistant gynecological cancers
This trial tests a personalized approach to treating advanced ovarian or endometrial cancers that have come back or stopped responding to standard treatments. It uses a special model to guide which therapy might work best for you.
Beijing, Beijing MunicipalityAges 18–80 - NCT06118502Recruiting
Adaptive quit-smoking treatment for early relapse
This trial tests a flexible treatment approach for smokers who want to quit and are at risk of relapsing early. It aims to help you stay smoke-free by adjusting the support you get.
Charleston, South CarolinaAges 21 years+ - NCT05809986Recruiting
Study of ofatumumab in adults with relapsing multiple sclerosis
This is an observational study (no random treatment) that follows adults with relapsing multiple sclerosis (RMS) who are taking ofatumumab. The study aims to better understand how patients do in real-world care while completing questionnaires and other scheduled check-ins.
AmadoraAges 18–99 - NCT04373473RecruitingPhase 2
Oral stool treatment to prevent ulcerative colitis flare-ups
This study tests whether taking freeze-dried (lyophilized) donor stool material by mouth can help prevent ulcerative colitis from coming back or causing intestinal inflammation. Participants are in remission and stay on their usual treatment while receiving the study product.
Houston, TexasAges 18 years+ - NCT01629017Recruiting
Long-term follow-up after a stem cell transplant
This study looks at the long-term health effects of hematopoietic (blood-forming) stem cell transplants. It may help doctors better understand and manage late side effects for children and teens after transplant.
Stanford, CaliforniaAges Up to 18 years - NCT06069141Recruiting
Comparing syphilis treatments for people with HIV
This study compares the standard treatment for early syphilis with a combination that includes an extra antibiotic, to see which is more effective. It is for people living with HIV who have early syphilis.
Hsinchu, TaiwanAges 18 years+ - NCT07087314RecruitingPhase 2
Study of an injection for nephrotic syndrome in children
This study tests an injection (SG301) that targets a protein called CD38 to help children whose nephrotic syndrome keeps coming back or depends on steroids. The goal is to see if the treatment can reduce relapses and the need for steroids.
Hangzhou, ZhejiangAges 6–18 - NCT06654154Recruiting
Vitamin B12 as a marker for disease activity in tocilizumab patients
This study looks at whether vitamin B12 levels in the blood can help tell if your disease is active or if you have an infection while being treated with tocilizumab. The goal is to find a simple way to monitor your condition without extra invasive tests.
Clermont-FerrandAges 18 years+ - NCT06529406RecruitingPhase 4
Switching from B-cell therapy to ozanimod in MS
This study tests whether people with stable MS who have been on a B-cell depleting therapy for at least 2 years can safely switch to a daily pill called ozanimod. It aims to see if this switch keeps MS under control and may be more convenient.
Aurora, ColoradoAges 18 years+
Hear when a new Relapsed or Refractory Large B-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapsed or refractory large b-cell lymphoma?
- Yes. Clin2 currently lists 1,747 recruiting relapsed or refractory large b-cell lymphoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsed or refractory large b-cell lymphoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsed or refractory large b-cell lymphoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Relapsed/Refractory Large B-Cell Lymphoma
- Refractory Diffuse Large B-Cell Lymphoma
- Refractory Primary Mediastinal Large B-Cell Lymphoma
- Diffuse Large B Cell Lymphoma Relapsed
- Relapsed/Refractory B-cell Lymphoma
- Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
- Relapsed or Refractory B-cell Lymphoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.